MFS
SWTX

Mirabella Financial Services’s SpringWorks Therapeutics SWTX Stock Holding History

Mirabella Financial Services’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-9,936
Closed -$474K – 479
2020
Q3 		$474K Buy
+9,936
New +$423K 0.07% 145

Other funds holding SWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Mirabella Financial Services's SWTX Position: Q4 2020 in Review

Mirabella Financial Services sold out of SpringWorks Therapeutics (SWTX) in Q4 2020, closing a stake of 9,936 shares — an estimated $474K sold.

Mirabella Financial Services first reported a position in SWTX in Q3 2020 and held it in 1 quarter. The position peaked at $474K in Q3 2020. 124 funds tracked by Wall St. Rank hold SWTX as of Q4 2020.

  • Mirabella Financial Services reported no remaining SpringWorks Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Mirabella Financial Services sold 9,936 SpringWorks Therapeutics shares in Q4 2020, an estimated $474K.
  • Mirabella Financial Services first reported a position in SpringWorks Therapeutics in Q3 2020 and held it in 1 quarter.
  • Mirabella Financial Services's SpringWorks Therapeutics position peaked at $474K in Q3 2020.
  • 124 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2020.

Based on Mirabella Financial Services's 13F filing for Q4 2020, filed 16 Feb 2021.